Durable Complete Response Achieved with Single Administration of Iopofosine I 131 

Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies

FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from a case study highlighting a durable complete response in a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) treated with iopofosine I 131.

The case study describes a 53-year-old woman with high-grade, double-hit DLBCL who had received four prior lines of therapy. This case demonstrates that a single administration of iopofosine I 131 produced a durable complete response lasting more than eight years in a patient with aggressive, relapsed DLBCL following multiple prior therapies and stem cell transplantation. The Company plans to submit these findings for journal publication or presentation at a medical meeting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.